While well tolerated, balovaptan did not improve socialization and communication difficulties in young persons with autism spectrum disorder compared with placebo, according to results of a clinical trial published in JAMA Psychiatry.
“Autism spectrum disorder is a common lifelong neurodevelopmental condition with an increasing global prevalence,” Eric Hollander, MD, of the department of psychiatry and behavioral sciences at Albert Einstein College of Medicine in New York, and colleagues wrote. “There is an unmet need for approved pharmacologic therapies targeting the